F04326 – Weight Management Trial – Injectable Treatment
We are looking for adults who are overweight to help evaluate a potential new weekly injectable treatment for weight management. The study involves regular health assessments and monitoring over approximately 79 weeks, including a 64-week treatment period. Excess weight is linked to a range of health conditions, including high blood pressure, high cholesterol, sleep apnea, and cardiovascular disease. This research could play an important role in helping people better manage their weight in the future.
Sign up below to see if this study is suitable for you.
Eligibility requirements
- Age: 18+
- Sex: M & F
- BMI: ≥30 or ≥27, with at least one weight-related comorbidity with at least one weight-related condition (e.g. high blood pressure, high cholesterol, sleep apnea, fatty liver disease, or cardiovascular disease).
- Weight: Stable (±5kg) for 3 months prior to screening.
- Medication: Participants must not have taken GLP-1 receptor agonists (e.g. Ozempic, Wegovy, Mounjaro) or other weight-loss medications within 6 months prior to screening, and cannot have previously used petrelintide or other amylin analog treatments. Various other medications are also prohibited, including certain antidepressants, antipsychotics, and systemic steroids.
- Medical History: Cannot have type 1 or type 2 diabetes. Exclusions include major depression or psychiatric disorder, history of cancer in the last 5 years (except for certain minor skin cancers), unstable cardiovascular disease (stable is ok), significant liver or kidney disease, and prior or planned weight-loss surgery or procedures.
- Smoking History: Nicotine and alcohol history and current use is collected and reviewed throughout the study.
Overnight Stays
- Nil.
Outpatient Visits
- There are approximately 19 visits in total over approximately 79 weeks, including in-clinic and remote check-ins.
Payment/Remuneration
- Participants who take part will receive all study medication, health assessments, and laboratory tests at no cost. They will also be reimbursed $250 for each in-clinic study visit to the site, including screening.
How to apply
To register your interest in this trial, please complete the form below, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.